|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Performance of liver stiffness measurements by transient elastography in chronic hepatitis显示文摘AIM:To compare results of liver stiffness measurements by transient elastography(TE) obtained in our patients population with that used in a recently published meta-analysis.METHODS:This was a single center cross-sectional study.Consecutive patients with chronic viral hepatitis scheduled for liver biopsy at the outpatient ward of our Infectious Diseases Department were enrolled.TE was carried out by using FibroScan(Echosens,Paris,France).Liver biopsy was performed on the same day as TE,as day case procedure.Fibrosis was staged according to the Metavir scoring system.The diagnostic performance of TE was assessed by using receiver operating characteristic(ROC) curves and the area under the ROC curve analysis.RESULTS:Two hundred and fifty-two patients met the inclusion criteria.Six(2%) patients were excluded due to unreliable TE measurements.Thus,246(171 men and 75 women) patients were analyzed.One hundred and ninety-five(79.3%) patients had chronic hepatitis C,41(16.7%) had chronic hepatitis B,and 10(4.0%) were coinfected with human immunodeficiency virus.ROC curve analysis identified optimal cut-off value of TE as high as 6.9 kPa forF ≥ 2;7.9 kPa forF ≥ 3;9.6 kPa for F = 4 in all patients(n = 246),and as high as 6.9 kPa for F ≥ 2;7.3 kPa for F ≥ 3;9.3 kPa for F = 4 in patients with hepatitis C(n = 195).Cut-off values of TE obtained by maximizing only the specificity were as high as 6.9 kPa for F ≥ 2;9.6 kPa for F ≥ 3;12.2 kPa for F = 4 in all patients(n = 246),and as high as 7.0 kPa forF ≥ 2;9.3 kPa forF ≥ 3;12.3 kPa forF = 4 in patients with hepatitis C(n = 195).CONCLUSION:The cut-off values of TE obtained in this single center study are comparable to that obtained in a recently published meta-analysis that included up to 40 studies. | Giovanna Ferraioli Carmine Tinelli Barbara Dal Bello Mabel Zicchetti Raffaella Lissandrin Gaetano Filice Carlo Filice Elisabetta Above Giorgio Barbarini Enrico Brunetti Willy Calderon Marta Di Gregorio Roberto Gulminetti Paolo Lanzarini Serena Ludovisi Laura Maiocchi Antonello Malfitano Giuseppe Michelone Lorenzo Minoli Mario Mondelli Stefano Novati Savino FA Patruno Alessandro Perretti Gianluigi Poma Paolo Sacchi Domenico Zanaboni Marco Zaramella | 2013 | World Journal of Gastroenterology2013，19，1： | 18 |
| 2 | Atlas of peritoneal histology 显示文摘 | Di Paolo N Sacchi G | 2000 | Perit Dial Int2000，203，： | 1 |
| 3 | Omental milky spots and peritoneal dialysis review and personal experience 显示文摘 | PAOLO N D SACCHI G GMMSI G | 2005 | Peritoneal Dialysis International2005，25，1： | 1 |
| 4 | Atlas of peritoneal histology显示文摘 | Di paolo N Sacchi G | 2000 | Perit Dial Int2000，203，： | 1 |
| 5 | Atlas of peritoneal histology显示文摘 | Di Paolo N Sacchi G | 2000 | Perit Dial Int2000，20，3： | 1 |
| 6 | Omental milky spots and peritoneal dialysis-review and personal experience显示文摘 | Nieola Di Paolo Giovanni Sacchi Guido Gnunsi | 2005 | Peritoneal Dialysis International2005，25，： | 1 |
| 7 | Atlas of peritoneal histology显示文摘 | Di Paolo N Sacchi G | | 0，，3： | 1 |
| 8 | Omental milkyspots and peritoneal dialysis - review and personal experience显示文摘 | Nicola Di Paolo Giovanni Sacchi Guido Garosi | 2005 | Immunol Peritoneal Memb2005，25，1： | 1 |
| 9 | Role of antiviral therapy in patients with chronic hepatitis B or C virus in preventing the development of hepatocellular carcinoma显示文摘Patients with chronic hepatitis B virus(HBV)and hepatitis C virus(HCV)infection are at significant risk for hepatocellular carcinoma(HCC).The most important risk factor associated with HCC is liver cirrhosis,which is again predominantly caused by chronic HBV or HCV infection.The most effective approach to avoid HCC development is to prevent HBV and HCV infection through vaccination.Indeed,HBV vaccine is the first vaccine demonstrated to prevent cancers.However,a vaccine for HCV is not available.Thus,the prevention of HCV-related HCC and to a large extent HBV-related HCC(among persons who are already chronically infected)will rely on antiviral therapy to prevent progressive liver disease.The evidence that these patients can effectively be protected against HCC risk by the treatment with antiviral therapy is rather controversial,due to the lack of randomized controlled trials(RCTs)that are ideally needed to establish the effi cacy,but are logistically and ethically challenging.Although the strongest evidence to support that antiviral therapy can prevent HCC should be derived from RCTs with HCC as an endpoint,it should be emphasized that clinical trials showing the efficacy of antiviral therapy on virus suppression or eradication,and/or improvement in liver histology can be considered indirect evidence that antiviral therapy can prevent HCC because high virus levels(in the case of HBV infection)and cirrhosis(in both HBV and HCV infection)are the most important risk factors for HCC. | Laura Scribano Veronica Vanin Giorgia Gottardo Diana Sacchi Francesco Paolo Russo | 2016 | Hepatoma Research2016，2，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员